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EXTREME SENSITIVITY AND THE PRACTICAL IMPLICATIONS OF RISK
ASSESSMENT THRESHOLDS
John Bukowski, DVM, PhD  WordsWorld Consulting
Mark Nicolich, PhD  Cogimet
R. Jeffrey Lewis, PhD  ExxonMobil Biomedical Sciences, Inc.
 Traditional risk-assessment theory assumes the existence of a threshold for non-cancer
health effects. However, a recent trend in environmental regulation rejects this assump-
tion in favor of non-threshold linearity for these endpoints. This trend is driven largely by
two related concepts: (1) a theoretical assumption of wide-ranging human sensitivity, and
(2) inability to detect thresholds in epidemiologic models. Wide-ranging sensitivity
assumes a subpopulation with extreme background vulnerability, so that even trivial envi-
ronmental exposures are hazardous to someone somewhere. We use examples from the
real world of clinical medicine to show that this theoretical assumption is inconsistent with
the biology of mammalian systems and the realities of patient care. Using examples from
particulate-matter air-pollution research, we further show that failure to reject linearity is
usually driven by statistical rather than biological considerations, and that
nonlinear/threshold models often have a similar or better fit than their linear counter-
parts. This evidence suggests the existence of practical, real-world thresholds for most
chemical exposures.
Keywords: threshold, non-cancer health effects, human sensitivity, epidemiologic models, particulate
matter, low-dose extrapolation
BACKGROUND
The traditional assumption in the field of quantitative risk assess-
ment (QRA) has been that non-cancer health effects are associated with
thresholds below which chemical exposures cause negligible risk (NRC
1983). This assumption forms the basis for the reference doses/concen-
trations within the Integrated Risk Information System (IRIS) main-
tained by USEPA (2011). But, there is an ongoing regulatory trend
toward an assumption that exposure concentration-response functions
may be linear (through the ordinate) for non-cancer health effects,
including such diverse and complex outcomes as death, heart disease,
and reproductive impairment. This trend is being driven largely by two
concepts: (1) a theoretical assumption of extreme sensitivity within the
diverse human population, and (2) an inability to detect thresholds in
epidemiologic models.
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1545 US Highway 22 East, Annandale, NJ 08801; Phone: 908-730-1107; Fax: 908-730-1192;
Email: r.jeffrey.lewis@exxonmobil.com
1
Bukowski et al.: Sensitivity and risk assessment thresholds
Published by ScholarWorks@UMass Amherst, 2014
In the 2006 proposed rule for particulate matter (PM) regulation, the
US Environmental Protection Agency (Federal Register 2006) acknowl-
edged that “it is reasonable to expect that there likely are biologic thresh-
olds for different health effects in individuals or groups of individuals
with similar innate characteristics and health status,” but that population
thresholds are unlikely due to extreme differences in sensitivity between
individuals. The Agency stated the following:
“Individual thresholds would presumably vary substantially from per-
son to person due to individual differences in genetic-level suscepti-
bility and pre-existing disease conditions ... Thus, it would be difficult
to detect a distinct threshold at the population level, below which no
individual would experience a given effect, especially if some mem-
bers of a population are unusually sensitive” (Federal Register 2006).
This idea is mirrored in the recent National Research Council (NRC
2009) report on advancing risk assessment at EPA, in which the authors
state that “noncarcinogens can exhibit low-dose linearity, for example,
when there is considerable inter-individual variability in susceptibility and
each individual has his or her own threshold.” A similar argument was
made by members of a recent EPA workshop on low-dose extrapolation,
in which a wide range of “individual thresholds” are assumed to be driv-
en by similarly wide differences in “background risk” (White et al. 2009).
The idea of near-infinite variation in sensitivity echoes arguments
posited within the environmental-justice literature, in which hypothe-
sized extreme sensitivity is purportedly due to social/racial stressors from
the environmental “riskscape” (IOM 1999; Morello-Frosch and Shenassa
2006). These stressors are said to act directly or indirectly through various
vague mechanisms such as “weathering,” allostatic load, chronic stress,
and wear and tear (Geronimus 1992, IOM 1999; Morello-Frosch and
Shenassa 2006). Researchers also speculate that “the body’s defense
mechanisms and ability to recover or detoxify have been compromised
through prior exposure to harmful agents” (Morello-Frosch and
Shenassa 2006).
A related argument suggests that even low-level exposures add to
background risks, enhancing ongoing disease-causing processes in a lin-
ear manner (Crawford and Wilson 1996; White et al. 2009). For practi-
cal purposes this argument can be seen as an extension of the sensitivi-
ty argument posited above, in that these hypothetical background risks
are thought to enhance individual sensitivity to other environmental
exposures.
The other commonly posed argument for non-carcinogenic, low-dose
linearity is that thresholds are difficult to detect in epidemiologic studies.
The EPA uses this inability of common epidemiologic models to detect
Sensitivity and risk assessment thresholds
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low-dose thresholds as support for their linearity arguments, noting that
“new epidemiologic studies have used different modeling methods to
address this question, and most have been unable to detect threshold lev-
els in the relationship between short-term PM [particulate matter] expo-
sure (generally using PM10) and mortality” (Federal Register 2006). The
previously cited workshop panelists repeat this idea, stating that “expo-
sure-response models ... [for] environmental toxicants with relatively
robust human health effects databases at ambient concentrations (eg,
ozone and particulate matter air pollution ...) do not exhibit evident
thresholds” (White et al. 2009). The NRC (2009) repeats this argument
yet again, noting that “There are multiple toxicants (for example, PM and
lead) for which low-dose linear concentration-response functions rather
than thresholds have been derived for non-cancer end points.”
In a recent paper, Rhomberg et al. (2011) evaluated these arguments
and rebutted them on a theoretical basis. These authors noted that the
extreme variability and sensitivity posited by proponents of linearity are
hypothetical arguments that ignore the reality of biological and disease
processes. That is to say, biological systems are highly regulated homeo-
static entities, and toxic states generally result when control mechanisms
are overwhelmed, leading to a cascade of events that cause disease.
Therefore, at low concentrations, the impacts of potentially toxic expo-
sures are both less common and less severe, producing negligible effects
at levels well below the toxic/therapeutic range. Rhomberg et al. (2011)
further point out that rather than being just theoretical assertions, their
arguments are backed by repeated empirical observation.
In the current paper, we attempt to place these arguments in per-
spective by highlighting the empirical evidence from clinical medicine,
and examining the practical limitations to the concept of extreme sensi-
tivity within human populations. This discussion updates and expands
upon an earlier paper (Bukowski and Lewis 2004). We also use mortality
from PM air pollution as an epidemiologic case study, pointing out exam-
ples where thresholds have been detected, and the statistical limitations
of assuming linearity in epidemiologic models.
THE CLINCAL REALITIES OF EXTREME SENSITIVITY
The non-threshold assumption is grounded in a belief that sensitivity
to chemical exposure lies along an almost infinite distributional range, or
at least that this range extends well beyond the 10-100-fold uncertainty
factors for inter-individual human variability typically applied to QRA.
This assumption implies that even trivial exposures are thought to pres-
ent a risk to some person or group within this highly diverse population.
Extreme sensitivity is said to reside within groups that are not always
addressed by traditional QRA, including children, senior citizens,
poor/minority populations, and those with preexisting illness or impair-
J. Bukowski and others
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ment. Factors that promote the enhanced sensitivity of individuals within
these groups have been referred to as determinants of “background risk”
(White et al. 2009; NRC 2009) or non-chemical “stressors” (Morello-
Frosch and Shenassa 2006; NRC 2009). The NRC (2009) calls for a for-
mal “vulnerability assessment that takes into account underlying disease
processes in the population.”
Acceptance of the above argument poses several unanswered ques-
tions, including: (1) are these groups inherently more sensitive to low-
level environmental exposures, (2) does the range of this enhanced sen-
sitivity encompass even trivial chemical exposures, (3) is such extreme
sensitivity compatible with existence, and (4) are extremely sensitive indi-
viduals already protected from environmental exposures? We address
these questions below.
Range of Variation
The extreme variation argument suggests that biological variability
spans multiple orders of magnitude, so that even trivial perturbations of
the homeostatic mechanism, as might occur from a few molecules of pol-
lution exposure, could push someone somewhere over the edge into
death or overt illness. Yet, this notion appears inconsistent with what is
already known about pathophysiology.
As Rhomberg et al. (2011) note, “we do not see continuous and grad-
ual gradation between people with normally functioning physiology
(...adequate to maintain basic functioning) and those who cannot main-
tain internal states in the face of environmental fluctuation or... cannot
carry out basic life processes.” Put another way, mammalian physiology
follows truncated rather than open-ended continuous distributions, with
extreme variation being incompatible with life. This can be observed by
examining basic clinical parameters (Table 1).
The normal ranges for clinical blood parameters do not encompass
all healthy individuals, but these ranges do suggest limits that cannot be
exceeded (Table 1). For example, a small minority of healthy people
might have an oxygen partial pressure (pO2) beyond the range of 80-100
mm/Hg, but no living person has a value of 8 or 1000, as suggested by the
extreme variation/sensitivity argument. Similarly, blood glucose levels of
8 mg/dL, leukocyte counts of 400, and potassium levels of 0.5 (or 50) can
be found only among those in danger of imminent death. Even for less
critical parameters such as ALT or bilirubin, order-of-magnitude
extremes are associated with clinical disease, not relative health. Rather
than wide-ranging variation, we see that human physiology functions
within relative narrow ranges, so that extremes of even 10-fold are rare
and often incompatible with life.
Sensitivity and risk assessment thresholds
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Extreme Sensitivity of Children
It is often assumed that children are more sensitive to pollutant expo-
sures. In a recent report on cumulative impacts of environmental expo-
sures, the California Environmental Protection Agency (CalEPA 2010)
cites potential differences in kinetics and inherent sensitivity as explana-
tions for enhanced risk among children. However, while it is certainly
true that there are cases where this is correct, it is not clear that it is uni-
versally true, or that this heightened risk would be great enough as to
approach extreme or near-infinite sensitivity.
Several authors have examined differential sensitivity between chil-
dren and adults and have concluded that although the physiology of chil-
dren may differ from that of adults, these differences are not uniformly
in the direction of increased sensitivity for children (Dourson et al. 2002;
J. Bukowski and others
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TABLE 1. Range of normal values for selected blood parameters across major systems.a
Test parameter Normal range
Liver/Digestive
Alanine aminotransferase (ALT) ≤ 48 U/L
Alkaline phosphatase 20-125 U/L
Amylase 60-180 U/L
Total bilirubin 0.3-1.0 mg/dL
Kidney
Blood urea nitrogen 7-30 mg/dL
Creatinine <1.5 mg/dL
Cardiovascular
Cholesterol <200 mg/dL
Creatinine kinase (total) ≤ 235 U/L (male)
≤ 190 U/L (female)
Low-density lipoproteins <130 mg/dL
Immune System
IgG 800-1500 mg/dL
Leukocyte (WBC) count 4.3-10.8 x 103
Oxygen Metabolism
Erythrocyte (RBC) count 4.1-54.9 x 106/mm3
pO2 80-100 mm/Hg
Endocrine
Cortisol 5-25 ug/dL (8 hour)
Fasting glucose 75-115 mg/dL
Reproductive/Endrocrine
Lutenizing hormone 0.8-26 mIU/mL (female)
Acid phosphatase ≤ 2.5 ng/mL (prostate)
Follicle-stimulating hormone 1.4-9.6 (female)
Serum Electrolytes/Proteins
Calcium 9-10.5 mg/dL
Sodium 136-145 mEq/L
Potassium 3.5-5 mEq/L
Plasma osmolality 285-295 mOsm/kg
Total protein 5.8-8.0 g/dL
aValues taken from Physician’s Desk Reference (2010)
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ECETOC 2005). In fact, children often have more rapid clearance of
chemical exposures, suggesting decreased overall sensitivity (Renwick
1998; Dourson et al. 2002). Using chemicals for which clearance data
were available for both children and adults, Dourson et al. (2002) con-
cluded that the average child/adult clearance ratio of 1.8 favored chil-
dren, suggesting that they were on average less sensitive than adults to
these select chemical exposures. Furthermore, for those instances in
which children were more sensitive, the 3.16-fold kinetic component of
the default intraspecies uncertainty factor covered the variation of 91% of
the chemicals tested (Dourson et al. 2002).
Premature infants do appear to have reduced clearance (Renwick
and Lazarus 1998), but this is a group that exists in a highly protected
hospital environment removed from exposures to airborne pollutants
and most chemical contaminants. Furthermore, premature infants would
largely lack the enzymes necessary to convert many potentially toxic
chemicals into their active forms (Renwick and Lazarus 1998).
Given that most of the chemicals examined by Dourson et al. (2002)
were pharmaceutical agents, it is possible to put these data in perspective
by comparing the child and adult dosages for these drugs, as well as for
others selected at random from the Physician’s Desk Reference (2010).
These dosages are based on clinical research, and encompass not only the
pharmacokinetic data examined by Dourson et al. (2002), but often issues
of absorption, distribution, and other pharmacodynamic factors as well.
In general, child dosages are not necessarily lower than those given to
adults (Table 2), which agrees with the findings of Dourson et al. (2002).
Furthermore, child/adult variation rarely differs by more than several-
fold, not the 10-100 factor used in QRA. This variation applies to highly
toxic cancer chemotherapeutics as well as more benign antibiotics and
antihistamines (Table 2).
On occasion, idiosyncratic effects from drugs like chloramphenicol
and tetracycline limit their use in children. However, these mechanisms
generally operate at therapeutic doses that are not relevant to the excep-
tionally low levels of exposure implied by extreme sensitivity. Allergic reac-
tions also limit drug use, but even allergens appear to exhibit thresholds
below which trivial exposures fail to elicit a reaction (Taylor et al. 2009).
Extreme Sensitivity of Other Subgroups
Other high-risk subgroups with background vulnerability are said to
include senior citizens and those with “underlying disease processes” or
poor “health status.” Specific conditions are often not well defined,
although respiratory, cardiovascular, and immune disorders have been
mentioned as background risks that could greatly enhance sensitivity to
environmental exposures (NRC 2009).
Sensitivity and risk assessment thresholds
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TABLE 2. Dosage instructions for common drugs used in children and adults.a
Adult Child 
Drug (mg/kg/d)b (mg/kg/d) Additional information
Antibiotics
Aztreonam 43-57 90-120 Dosages assume moderate-severe infection
Halve dosage in moderate renal impairment
Cefotaxime 43-86 50-180 Child dose for 1 mos to 12 years (neonate
100-150 mg/kg/d)
Halve dosage in renal impairment
Ceftibuten 6-9 9 Reduce adult dose to 2.25 mg/kg/d in mod-
erate to severe renal impairment.
Ceftriaxone 14-29 50-75 Do not exceed 2000 mg/d if both hepatic
and renal disease
Cephpodoxime 2.8-11 10 No adjustment needed for cirrhosis
No adjustment needed in elderly
Halve dosage if severe renal impairment
Ciprofloxacin 7-21 20-40 Similar safety/efficacy in elderly
5-14 mg/kg/d in renal impairment
Trimethoprim 8 5 Given in combination with sulfa
Dosage for urinary tract infection
50% reduction with moderate renal failure
Antifungals/Antivirals
Fluconazole 1.4-2.8 3-6 Dosage for esophageal candidiasis
Halve dosage in moderate renal impairment
5.7 mg/kg/d for prophylaxis in bone mar-
row transplantation
Valacyclovir 43 (for 7 d) 60 (for 5 d) Treatment for herpes zoster (adult) or
chicken pox (child)
7-14 mg/kg q 12-24 hours (7-28 mg/kg/d)
in renal impairment
Muscle Relaxants
Atracurium 0.4-0.5 mg/kg 0.3-0.4 mg/kg Given IV with anesthesia
Pediatric dose for infants (older children
given adult dosage)
Similar safety/efficacy in elderly
Pipecuronium 70-85 mcg/kg 40-57 mcg/kg Given IV with anesthesia
50-70 mcg/kg in adults with renal impair-
ment
Narcotics/Tranquilizers
Alfentanil 0.13-0.24 mg/kg 0.03-0.05 mg/kg Dosage for induction of analgesia
Shorter half-life in children
Longer half-life in elderly and those with 
hepatic disease
Buprenorphine 0.017 0.008-0.036 Halve dosage in “high-risk” patients (eg, eld-
erly, liver disease, respiratory disease)
Chlorpromazine 0.57-2.1 2.2-3.3 Dose to control nausea
Elderly started at lower range of dose
Use with caution in those with kidney, liver,
or cardiovascular disease
Hydroxyzine 200-400 mg/d 50-100 mg/d Use cautiously in elderly and begin at lower
therapeutic range
Anticancer/Immunosuppressive Drugs
Busulfan 0.06 0.06 Induction dose for cancer
Use cautiously in elderly and begin at lower
therapeutic range
continued…
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Liver and kidney disease
Drug dosage recommendations often include reduced dosages for
those with liver or kidney disease (Table 2). However, most suggested
reductions range from half to one quarter of the dose given to healthy
adults, rather than the orders of magnitude reductions suggested by the
extreme vulnerability argument used in QRA. Often, clinicians are
admonished only to “use with caution” in those with potential organ
impairment.
Senior citizens
Cautionary dosage statements are often applied to the elderly as well,
not because of special vulnerability, but because seniors are more likely to
have subclinical organ impairment compared to younger patients. As
with children, older adults in good health do not appear to be inherent-
ly more susceptible to clinical drug effects (Table 2).
Variation in genetic polymorphism
Genetic polymorphism accounts for much of the variable impact in
drug therapy, with enzymes such as those in the cytochrome P450
Sensitivity and risk assessment thresholds
137
TABLE 2. Continued
Cyclophosphamide 40-50 (IV) 40-50 (IV) Reduce if low WBC or if combined with 
1-5 (oral) 1-5 (oral) other agents
Methotrexate 7.5 mg/week 4.5 mg/week Dosage for adult or 10 kg child with 
(10 mg/m2/wk) rheumatoid arthritis
Elimination reduced with impaired renal
function
Nelarabine 1500 mg/m2 650 mg/m2 Closely monitor if kidney or liver disease
d 1,3,5 d 1-5
Thioguanine 2 2 Use cautiously in elderly and begin at lower
therapeutic range
Vinblastine 3.7-18 mg/m2 2.5-7.5 mg/m2 Induction dose
Halve dosage in hepatic disease
Cardiac/Respiratory Agents
Chlorpheniramine 16-24 mg/d 8-12 mg/d Pediatric dose for 6-12 year old
Use cautiously in elderly and begin at lower
therapeutic range
Digoxin 0.002-0.007 0.01-0.015 Maintenance dose for adult or 2-5 yr. child
0.001.5-0.003 mg/kg/d if creatinine clear-
ance < 40 mL/min
Fexofenadine 120-180 mg/d 30 mg/d Adult dose for child ≥12 yrs.
(0.5-1 yr.) Halve dosage in renal dysfunction
60 mg/d 
(2-11 yr.)
Theophylline 4.3-8.6 12-20 Pediatric dose for child <45 kg
Do not exceed 400 mg/d among high-risk
groups (eg, liver/kidney disease, elderly, or
heart failure)
aData taken from Physician’s Desk Reference (2003, 2010) or appropriate package insert
bUnits converted to mg/kg/d unless otherwise indicated
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(CP450) family playing a major role in lack of response or adverse reac-
tions (Johansson and Ingelman-Sundberg 2011). Between-person differ-
ences in individual CP450 enzymes can span 1-2 orders of magnitude
(Zhou et al. 2009).
Although genetic differences influence idiosyncratic drug responses,
they do not necessarily translate into wide-ranging differences in chemi-
cal toxicity among the general population. For example, recommended
dosage ranges for pharmacotherapeutics rarely span orders of magnitude
(Table 2). Furthermore, research has not necessarily shown wide varia-
tion in toxicity of common xenobiotics. One study of 14 drugs and chem-
icals that covered a wide range of toxicant classes found little variation in
toxicity across 85 different human lymphoblast cell lines, except for two
chemicals (perfluorooctanoic acid and phenobarbital) in which variabil-
ity ranged from approximately 2-5 fold (O’Shea et al. 2011). Similarly,
research among workers occupationally exposed to butadiene has shown
little genetic variability in metabolism, with most results spanning a factor
of two or less (Fustinoni et al. 2002; Albertini et al. 2001, 2003, 2007).
The impact of genetic polymorphism would also be greatly lessened
within the context of extremely low doses. The high doses that produce
therapeutic or toxic effects can kill cells, alter homeostasis, overwhelm
repair mechanisms, saturate enzyme pathways, and deplete co-substrates.
Genetic polymorphism forms an important modifying factor for these
high-level processes (Slikker et al. 2004) but should have little impact on
the orders-of-magnitude lower exposures implicated under the extreme
sensitivity argument.
Background disease status and the impact of competing risks
Theoretical arguments in favor of extreme vulnerability suggest that
those with existing disease conditions would be at greatest risk from low-
level environmental exposures. In the real world of clinical medicine, rec-
ommendations for the management and protection of these most sensi-
tive individuals are embodied within the formal practice guidelines and
position papers developed by expert committees and professional associ-
ations. These cover conditions such as chronic obstructive pulmonary dis-
ease (COPD), immune suppression, chronic liver or kidney disease, and
cardiovascular disorders (Table 3). Under the extreme sensitivity argu-
ment, such individuals would be the ones hypothetically most impacted
from ever diminishing pollution exposure.
Expert guidelines on the management of important conditions such
as cardiovascular disease (and associated risk factors), hepatitis, and
immune suppression stress two main needs: proper treatment and modi-
fication of personal behaviors (Table 3). Proper treatment includes phar-
macotherapy, surgical interventions (eg, procedures to control heart rate
in atrial fibrillation), and adjunct therapies (eg, oxygen for COPD).
Behavioral modification involves education and support for weight reduc-
J. Bukowski and others
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TABLE 3. Summary of major practice guidelines for management of selected chronic diseases. 
COPD
(O’Donnell et al. 2008; Qaseem et al. 2007)
Smoking cessation
Prevention of respiratory infection (vaccination, etc.)
Spirometry to monitor progression
Adherence to appropriate pharmacotherapy
Avoidance of allergens and respiratory irritants
Oxygen therapy for hypoxia
Pulmonary rehabilitation (exercise, diet, weight control, behavioral modification, etc.)
Chronic Hepatitis (Hep B or C virus)
(Dienstag and McHutchison 2006; Wejstal et al. 2003; Weinbaum et al. 2008; Lee et al. 2010)
Limitation or discontinuation of alcohol intake
Smoking cessation
Caution in using new drugs or herbals that may harm liver
Education on behavioral modification and reducing the risk of transmission through sex, blood
products, etc.
Adherence to appropriate treatment with antivirals and immune stimulants
Hepatitis A vaccination
Management of comorbid conditions (eg, HIV, immune suppression, etc.)
Periodic exams and monitoring of viral levels
Screening for liver cancer
Chronic Kidney Disease (including post-transplant)
(Hogg et al. 2003; Burden and Tomson 2005; Chan et al. 2011)
Diagnosis and treatment of comorbid conditions (eg, hyperlipidemia, cardiovascular disease,
hypertension, and diabetes)
Adherence to appropriate pharmacotherapy
Dialysis to replace kidney function
Monitoring kidney function with glomerular filtration rate and proteinuria levels
Nutritional support to combat anemia, osteoporosis, diabetes, dyslipidemia, and hypertension
Exercise and weight control
Smoking cessation and limiting alcohol intake
Psychosocial support
Heart Disease (and related factors)
Metabolic Syndrome (Novo et al. 2008; Graham et al. 2007; Grundy et al. 2005)
Patient education as to weight loss, increased exercise, and other behavioral modifications
Control of hyperlipidemia and hyperglycemia through diet and medication
Smoking cessation
Chronic Stable Angina (Gibbons et al. 2003)
Adherence to appropriate pharmacotherapy (eg, aspirin, ACE inhibitors, and beta blockers)
Lifestyle changes such as weight loss, increased exercise, and improved diet
Appropriate pharmacotherapy to manage risk factors such as diabetes, hypertension, and
hyperlipidemia
Surgical revascularization (if appropriate)
Heart Failure
(Jessup et al. 2009; Mant et al. 2011)
Management of comorbid conditions such as hypertension and diabetes
Adherence to appropriate pharmacotherapy (eg, ACE inhibitors and beta blockers)
Advanced electrical therapy (if appropriate)
Exercise rehabilitation with psychosocial and educational support
Ongoing monitoring of disease progress
Smoking cessation and alcohol reduction
continued…
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tion, proper nutrition, increased exercise, smoking cessation, alcohol
reduction, and other factors that improve organ function and reduce the
risk of further damage.
Practice guidelines do not include any caution about exposure to low
levels of pollution, trace chemicals, or disinfection byproducts. In fact,
chemical disinfectants are widely used to guard against infection. In cases
of serious respiratory diseases such as COPD, avoidance of irritants is rec-
ommended, but this refers to combustion products and chemical irritants
at levels high enough to cause frank respiratory irritation, not the low-
level ambient exposures suggested by extreme sensitivity arguments.
In extreme immune suppression, isolation under conditions of steril-
ization, HEPA-filtered air, and limited access to outside people may be
recommended, but this is to limit transmission of pathogens or oppor-
tunist organisms, not pollutants (Dadd et al. 2003; Sehulster and Chinn
2003). In fact, mortality rates for patients in strict isolation under HEPA
filtration and positive pressure are similar to those associated with less
stringent approaches that mainly limit visitors and stress hand washing
and face masks (Ogden et al. 1990; Dadd et al. 2003). This suggests that
completely removing all air pollution exposure is of no apparent benefit,
and that most of the risk among highly vulnerable immune-suppressed
patients resides with endogenous microorganisms and close contacts, not
exogenous exposures.
Guidelines for extreme immune suppression may also restrict food
and water, including avoidance of certain foodstuffs. These again are
based on concerns for microbiological exposure, not chemical contami-
nants. In fact, highly processed foods and juices, and highly disinfected
municipal drinking water, are all acceptable despite the fact that such
consumables contain numerous chemical byproducts. In some instances,
J. Bukowski and others
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TABLE 3. Continued
Immune Suppression (bone-marrow transplant)
(Ogden et al. 1990; Kruger et al. 2005; Dadd et al. 2003; Yokoe et al. 2009)
Initial protective isolation (rooms with HEPA filtration, laminar flow, positive pressure, etc.) if
appropriate based on neutropenia
Reverse isolation procedures that stress hand washing and face masks
Appropriate prophylactic antibiotics, antifungals, and antivirals
Initial restriction of visitors and screening out those with rash, colds, etc.
Strict hand hygiene after preparing food, bowel movements, touching animals, going outdoors,
and other activities associated with bacteria
Avoidance of gardening, excavation sites, or other soil exposures
Avoidance of or limiting exposure to animals or their feces (eg, farming, grooming, veterinary
practice, cleaning litter)
Avoidance of water from lakes, ponds, or private wells (municipally treated water okay)
Avoidance of undercooked meat, fish, and eggs
Low-microbial diet that restricts certain foods such as raw nuts
Water filtration/boiling to avoid cryptosporidium
Safe sex
11
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water filtration or boiling is suggested, but only to remove the risk of
Cryptosporidium infection (Yokoe et al. 2009).
It is tempting to ignore the import of practice guidelines under the
notion that healthcare professionals deal with clinical situations and
would therefore be unaware of the more subtle effects of environmental
exposures. But rather than ascribe ignorance to the practitioner, we need
to recognize that doctors and nurses must deal with the realities of
patient care, in which important competing risks dwarf the hypothetical
impact of trace-level environmental exposures.
Clinicians recognize that immune-suppressed individuals are most like-
ly to succumb to infection or some other aspect of bone-marrow depression
(eg, bleeding disorders or anemia), matters unrelated to low-level expo-
sures to chemical pollutants. By the same token, it is much more important
for those with COPD to stop smoking, limit exposure to high-level irritants,
and guard against weight gain, malnutrition, anemia, heart disease, and
other comorbid conditions associated with disease progression (O’Donnell
et al. 2008). Similarly, adherence to proper treatment, nutritional manage-
ment, exercise, control of hypertension, psychosocial support, and many
other factors are much more important in the management of chronic con-
ditions such as heart disease and kidney failure (Table 3).
Based on the clinical guidelines, it would seem that low-level environ-
mental exposures have negligible impact on patient health in the face of
important known risks for disease progression. Put another way, real-
world competing risks tend to trump concerns about hypothetical trace-
level exposures to pollutants. That is to say, it is very unlikely that some-
one would be healthy enough to survive the gauntlet of major competing
risks, only to be felled by trace-levels of ambient PM2.5 or ozone.
Clinical Protection of those at Highest Risk
Justification for the extreme sensitivity argument requires a population
of excessively debilitated individuals who would be most vulnerable to even
minor environmental exposures. This would include patients with severe
respiratory impairment or immune dysfunction. Yet, best clinical practice
tends to incidentally minimize pollution exposure in these very individuals.
For example, those with advanced COPD are maintained on oxygen for
most of the day, limiting exposure to ambient air (Qaseem et al. 2007;
O’Donnell et al. 2008). Of even more relevance, patients at highest risk
from immune suppression, such as those undergoing bone marrow trans-
plants, may be kept in protective isolation that includes HEPA filtration,
laminar flow, and positive pressure (Dadd et al. 2003; Sehulster and Chinn
2003). Premature infants are similarly isolated. An extreme example would
be a so-called “bubble boy” existence, in which an individual with severe
immune depression lives in an artificial environment devoid of outside con-
tact (Guerra and Shearer 1986). Such protective practices would remove all
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or most ambient exposures, so that those at highest hypothetical risk of
effect would be at lowest actual risk of exposure.
Even if severe protective practices were not in place, it is doubtful that
very low-level pollution exposures would negatively affect even the most
vulnerable described above. Referring again to the switch from restrictive
isolation practices to less restrictive “reverse isolation” procedures, restric-
tive HEPA filtration and positive air pressure essentially remove exposure
to all ambient pollution, yet switching to less stringent procedures has pro-
duced little difference in patient mortality. This highlights the fact that the
main risk to those with severe immune dysfunction is from endogenous
organisms and close contacts, not external exposures (Dadd et al. 2003).
STATISTICAL CONSIDERATIONS FOR THRESHOLD DETECTION IN PM
STUDIES
Interpretation of the data from risk assessments almost always involves
statistical evaluation. In this section we discuss how statistical considera-
tions such as model choice can influence identification of nonlinear rela-
tionships, and how these considerations may have combined to obscure
thresholds in air pollutions studies of acute or chronic mortality. A more
in-depth discussion of statistical issues involved in model choice can be
found in Nicolich and Gamble (2011).
Model Choice
Regulatory agencies often base safety standards on interpretation of
statistical models. However, different models applied to the same data can
lead to different conclusions, highlighting the importance of choosing
the appropriate model. Reliance on inappropriate models can lead to
either overly lax standards that jeopardize health or overly stringent ones
that suppress economic benefits by requiring expensive, but needless,
remediation and prevention strategies.
Some agencies apply models based on the concept of a Threshold of
Toxicological Concern (TTC) which is “a pragmatic risk assessment tool
that is based on the principle of establishing a human exposure thresh-
old value for all chemicals, below which there is a very low probability of
an appreciable risk to human health” (Kroes et al. 2004). This approach
has been adopted (for some applications) by the US Food and Drug
Administration (FDA) and several European agencies (Kroes et al. 2000,
2004, 2005; EFSA 2004). Some agencies apply models based on a related
concept called the Threshold of Regulation (TOR), which posits that
there is a de minimis risk level below which regulation is unwarranted.
The EPA has proposed applying the TOR rules to pesticide regulation
(Federal Register 2002). Both concepts (TTC and TOR) recognize the
practical existence of a threshold without necessarily committing to a
functional threshold model.
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However, air pollution standards developed by the EPA are generally
based on strict linear no-threshold concentration-response (CR) models
from epidemiologic studies, rejecting or ignoring thresholds unless the
assumed linear relationship can be proven wrong (USEPA 2009; OAQPS
2005). Therefore, one reason that the EPA and its advisers may fail to
detect thresholds is that they begin with models that do not address the
existence of a threshold.
In essence, the approach used by EPA assumes a linear, no-threshold
relationship unless proven otherwise. In this case, the “proof” relies on
statistical tests that have weak power to detect nonlinearity in the typical
situation with few observations in low-concentration range of the CR
model. This makes it difficult to reject the no-threshold assumption even
in the face of apparent nonlinearity (Li and Li 2008). Such an approach
also ignores a basic tenet of traditional hypothesis testing, which cautions
against accepting the null assumption simply because you failed to reject
it (Daniel 1991).
Exposure misclassification, which is a common problem in environ-
mental epidemiology, also tends to obscure thresholds. In air pollution
studies, exposure assessment typically relies on area-wide measurements
that are not highly correlated with personal exposures. Using time-series
data, Brauer et al. (2002) demonstrated that the resulting exposure mis-
classification tends to obscure the presence of a threshold when it exists.
The importance of using the correct CR function is widely acknowl-
edged as “a critical component in interpreting health risks associated with
ambient PM concentrations” (OAQPS 2003), which is “important from
both an etiologic and regulatory perspective” (Abrahamowicz et al. 2003).
In fact, the EPA has stated that the “single most important factor influ-
encing the uncertainty associated with the risk estimates was whether or
not a threshold concentration exists below which PM-associated health
risks are not likely to occur” (OAQPS 2003). Therefore, a search for the
correct model should include looking for nonlinearity rather than simply
assuming linearity.
Choosing the appropriate model can be difficult given the typical sit-
uation in which there are relatively few data points in the low-exposure
region wherein thresholds typically lie. Applying a linear model to such
data will greatly overestimate risk at low concentrations and underesti-
mate the risk at higher concentrations (Figure 1). Under this typical sit-
uation of few data points below the threshold, hypothesis tests will usual-
ly fail to reject linearity (Robins and Greenland 1986).
Thresholds in Acute-Mortality Data
Much of the support for a significant effect from low-level exposure
to PM and other pollutants resides within time-series (TS) studies that use
complex linear models to link daily fluctuations in pollution to daily mor-
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tality. In a number of instances, investigators have reanalyzed these data
and shown that nonlinear models produced as good or better fit than the
original linear ones, and that thresholds could often be statistically
demonstrated (Table 4).
Mortality displacement
One concern in TS models of acute mortality is so-called harvesting or
mortality displacement, wherein exposure hastens the deaths of a frail sub-
set of the population that already has a short life expectancy, independent
of exposure to PM. Most studies investigating this concept have concluded
that mortality displacement would have only a small impact on the relative
effects of PM (Dominici et al. 2003; Murray and Lipfert 2010; Murray and
Nelson 2000; Schwartz and Zanobetti 2000; Smith et al. 1999; Zanobetti et
al. 2000; Zeger et al. 1999). However, Roberts (2011a, b) showed that in
some situations, mortality displacement can alter the shape of the CR curve
so as to mask a mortality threshold. Although further work needs to be
done, these initial findings suggest that apparently linear, no-threshold
effects may in some cases be an artifact of mortality displacement.
Thresholds in Chronic-Mortality Data
The effects of PM have also been explored with cohort studies of
chronic-disease mortality. Some of these have found consistent and sig-
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TABLE 4. Time-series studies of PM mortality that have been reanalyzed using nonlinear/threshold
models. 
City/Data Set Results
Philadelphia, PA Kelsall et al. (1997) reported a significantly increased relative risk (RR 1.01) for
subjects ≥75 years of age, with no apparent threshold.
Nicolich and Gamble (1999) reported that a threshold model better fit the
data and produced a threshold around 125 mg/m3 total suspended particu-
lates (TSP).
Birmingham, AL Schwartz (1993) reported a linear trend, no evidence of a threshold below 20
μg/m3 PM10, and a non-significant test for nonlinearity (p=0.70).
Samet et al. (1995) used a categorical approach and reported a nonlinear
trend with increased risks only at concentrations above 40-60 μg/m3.
Smith et al. (2000a) reported possible thresholds of 55-75 μg/m3 using four
different modeling approaches.
St. Louis, MO Dockery et al. (1993) reported a 1.6% linear increase in total mortality for
each 10 μg/m3 increase in PM10.
Samet et al. (1995) reanalyzed the data by quintile and found no overall pat-
tern of increasing mortality with increasing PM10.
Utah Valley, UT Pope et al. (1992) reported a significant linear association between daily mor-
tality and PM10 in Utah Valley between 1985-1989. Test for nonlinearity and
thresholds were not significant.
Samet et al. (1995) reported that the most plausible model produced a no-
effect threshold.
Chicago, IL Samet et al. (2000) performed a linear analysis that suggested a 0.05% increase
in mortality for each 10 μg/m3 increase in PM10.
Smith et al. (1997) found a nonlinear (but biologically implausible) relation-
ship between PM10 and mortality.
Using piecewise linear analysis, Roberts (2004) could not reject linearity on
statistical grounds, but found that “graphical presentations strongly suggest the
existence of thresholds.”
Using statistically smoothed CR functions with varying lags, Moolgavkar
(2003a) reported that the most plausible model comparing PM10 to mortality
had an obvious threshold at about 60 μg/m3.
Phoenix, AZ Mar et al. (2000) reported a weak linear association between total mortality
and coarse PM (PM2.5-10), but no associations with PM2.5.
Smith et al. (2000b) reported a significant linear relationship between mortali-
ty and coarse PM (PM10-2.5) but not PM2.5.
In a second analysis similar to that used for the Birmingham data, Smith et al.
(2000a) found nonlinear associations.
Daniels et al. (2004) used a Bayesian model that suggested a PM10 threshold at
approximately 60 μg/m3.
Los Angeles, CA Moolgavkar (2003b) reported significant linear associations between PM10 and
mortality 2-4 days after exposure, and for PM2.5 exposure on the day of death,
but data suggested possible thresholds of 50-70 μg/m3 for PM10 and 45-65
μg/m3 for PM2.5.
Daniels et al. (2004) reported a nonsignificant linear association between mor-
tality and PM10, but his Bayesian model suggested a threshold at or above
approximately 75 μg/m3 PM10.
20 largest cities Daniels et al. (2004) report no evidence of a threshold for total or cardiovascu-
lar/respiratory mortality down to 10 μg/m3 PM10.in NMMAPS
Stylianou and Nicolich (2009) used validated alternative models on 9 of the 20
cities and reported that effects were not uniform across the nine cities, and
that many models exhibited thresholds of approximately 25–45 μg/m3 PM10.
Smith et al. (2009) report evidence of nonlinearity over 0-40, 40-60, and 60-80
ppb O3 intervals for 98 cities with coefficient significance shifts within a 25-40
ppb threshold range.
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nificant associations between PM and death (Dockery et al. 1993; Pope et
al. 2002), whereas others have not (Abbey et al. 1999; Lipfert et al. 2000).
However, results from the American Cancer Society (ACS) cohort, which
is the largest and most influential study, suggest significant association
between PM exposure and either cardiopulmonary, lung-cancer, or all-
cause mortality (Pope et al. 2002).
Cohort analyses typically rely on the Cox proportional hazards (PH)
model, which considers time to an event (eg, death) under the influence
of an outside exposure concentration (eg, PM). This model is built
around the hazard function, which is based on the probability that the
event will occur in the next short interval of time t (assuming it has not
yet occurred). Mathematically, the time to the event is directly related to
the hazard function, so that changes in the hazard directly affect sur-
vivorship. The Cox model is robust and effective for this type of analysis
because it does not make assumptions about the form of the hazard func-
tion; only that exposure has a proportional effect on hazard. This allows
considerable flexibility regarding the form of baseline survivorship, and
direct estimation of covariate effects (assuming that covariates also have
a multiplicative effect on the hazard function) (Harrell 2010).
An unfortunate limitation of the Cox model is that its standard form
is not compatible with thresholds, because there is a basic assumption of
proportional hazard across exposure concentrations (ie, the hazard func-
tion increases at all concentrations above zero) (Harrell 2010).
Therefore, it is not surprising that thresholds have not been readily iden-
tified in cohort studies, given that a basic assumption of the standard
modeling approach does not permit them. Additional research has also
raised concerns about the Cox assumption of proportionality over the
range of PM concentrations in the ACS study, suggesting the possibility of
a threshold (Abrahamowicz et al. 2003).
Graphical evidence
In some instances, the USEPA and study investigators have failed to
acknowledge nonlinearity that was statistically insignificant, but graphi-
cally evident. This highlights a key problem of relying on weak statistical
tests as the sole arbiter of linearity/thresholds.
For example, results from the ACS cohort study are used to support
the USEPA’s stance that PM is linked to mortality in a linear fashion with-
out an apparent threshold. Based on Cox PH results, authors of the ACS
study reported significantly increased risks for PM that “were not signifi-
cantly different from linear.” However, nonparametric smoothed graphs
showed apparent departures from linearity, primarily in the region of low-
est exposure (Pope et al. 2002). This is mirrored in graphs taken from an
earlier iteration of the study (Figure 2), in which the Health Effects
Institute noted departures from linearity during flexible analyses
(Krewski et al. 2000). In all cases there was evidence of apparent thresh-
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FIGURE 2. Shape of the CR function using standardized residuals generated during analysis of data
from the ACS cohort (Adapted from Krewski et al. 2000). Graphs copied from reanalysis of the orig-
inal ACS data performed by Krewski et al. (2000). 
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olds, given that the plots of the residuals from the linear model are not
flat and the plots for all-cause mortality and cardiopulmonary mortality
show negative residuals below approximately 15 µg/m3 (Krewski et al.
2000; Pope et al. 2002).
CONCLUSIONS
Research in disciplines ranging from business to patient care has
addressed the problem of “silos,” whereby professionals in one discipline
work within that restricted environment without tapping into the breadth
of knowledge and experience in the wider universe of science, medicine,
and engineering (Lunn 1997; Conway 1997). Such may be the case for
QRA, with some risk assessors so highly focused on the theoretical world
of hypothetical risk that they tend to lose sight of the practical realities of
the world around them. In the hypothetical world, theories about
extreme sensitivity and vulnerability make sense and support models that
fail to demonstrate nonlinearity. But these theories break down under the
pathophysiologic realities of human biology and medicine.
The extreme sensitivity argument is predicated on a population with
extreme background vulnerability, so that even trivial exposures can be
viewed as hazardous to their fragile state. In this paper, we offer several
scientific arguments that bring this assumption into question:
1. The tightly regulated homeostasis of mammalian systems suggests
that extreme sensitivity/variability is usually incompatible with life.
2. From a clinical standpoint, groups such as children and seniors are
not inherently highly sensitive, and appear to have a range of sus-
ceptibility not greatly different from that of middle-aged adults.
3. Those with the highest background disease vulnerability would likely
succumb to real-world competing risks that dwarf any hypothetical
hazard from trace-chemical exposures.
4. The most highly vulnerable are often isolated from pollution, pre-
cluding impacts from such exposures.
All this argues for practical, real-world thresholds for most chemical expo-
sures.
The recent regulatory trend has been to assume linearity in concen-
tration-response unless proven otherwise. To this end, linear models are
proposed and then rejected only if significant departures from linearity
can be demonstrated. This violates the basics of hypothesis testing, in that
failure to reject a model does not prove its appropriateness. Furthermore,
the tests used to assess thresholds often have weak power and will fre-
quently fail to reject even in the presence of nonlinear trends. Frequently,
nonlinear/threshold models have a similar or better fit than their linear
counterparts, especially for the typical situation in which the majority of
J. Bukowski and others
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data are at the higher levels of exposure away from the threshold region.
The theoretical world of extreme vulnerability is inconsistent with the
biology of mammalian systems and clinical medicine. Therefore, rather
than pursuing ever-diminishing exposures in an effort to protect an ever-
diminishing hypothetical population, resources would seem better directed
toward the competing risks of greater magnitude and proven importance.
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